| dc.contributor.author | Makowska, Marta | |
| dc.date.accessioned | 2013-04-12T07:47:37Z | |
| dc.date.available | 2013-04-12T07:47:37Z | |
| dc.date.issued | 2012 | |
| dc.identifier.issn | 1899-2226 | |
| dc.identifier.uri | http://hdl.handle.net/11089/1526 | |
| dc.description.abstract | Within last twenty years in the European Union much regulation concerning advertisements of drugs changed. The aggressive
marketing operations of producers of medicines caused that new solutions, not only legal but also ethical, had appeared.
The European Union is imposing reliable solutions upon its members in the form of directives to which they must adapt their law.
They can however decide to choose stricter law than the one which is recommended to them.
The European Federation of Pharmaceutical Industry and Associations – voluntary organization consisting associations
of pharmaceutical companies from lots of countries is acting on similar principles. Each of the members belonging to it can implement its
own, more restrictive regulation in the national ethical code than a Federation is ordering.
Main purpose of this article is reading what legal and ethical solutions of pharmaceutical marketing were accepted in selected countries
of the European Union. Whether they are stricter than the ones imposed upon them by European Union? How in this background Polish
regulations are looking like?
In the article also examples of the law-breaking and ethical principles by producers of medicines in the European Union will be
presented. It will show sanctions taken out towards them for this reason. A question will be put: are various penalties able effectively to scare
the pharmaceutical industry off the unethical or even unlawful advertising? | pl_PL |
| dc.language.iso | pl | pl_PL |
| dc.publisher | Salezjańska Wyższa Szkoła Ekonomii i Zarządzania | pl_PL |
| dc.relation.ispartofseries | Annales. Etyka w życiu gospodarczym;2012, vol. 15, nr 1 | |
| dc.subject | pharmaceutical companies | pl_PL |
| dc.subject | physicians | pl_PL |
| dc.subject | professional ethics | pl_PL |
| dc.title | Lekarze i firmy farmaceutyczne – standardy etyczne wzajemnych relacji w Unii Europejskiej | pl_PL |
| dc.title.alternative | Physicians and Pharmaceutical Companies – Ethical Standards of the Cooperation in the European Union | pl_PL |
| dc.type | Article | pl_PL |
| dc.references | Carpenter G., Italian Doctors Face Charges over GSK Incentive Scheme, „The Lancet” 2004,
nr 363. | |
| dc.references | Dieners P., M. Oeben, Germany [w:] The International Comparative Legal Guide to Pharmaceutical
Advertising 2010. A Practical Insight to Cross-border Pharmaceutical Advertising
Work, red. Global Legal Group, Global Legal Group, London 2010. | |
| dc.references | Drouault-Gardrat P., France [w:] The International Comparative Legal Guide to Pharmaceutical
Advertising 2010. A Practical Insight to Cross-border Pharmaceutical Advertising
Work, red. Global Legal Group, Global Legal Group, London 2010. | |
| dc.references | Dz. U. 2001 nr 126 poz. 1381, Ustawa Prawo farmaceutyczne. | |
| dc.references | Dz. U. 2008 nr 210 poz. 1327, Rozporządzenie Ministra Zdrowia w sprawie reklamy produktów
leczniczych. | |
| dc.references | Dz. U. 2008 nr 45 poz. 271, Obwieszczenie Marszałka Sejmu Rzeczypospolitej Polskiej
w sprawie ogłoszenia jednolitego tekstu ustawy – Prawo farmaceutyczne. | |
| dc.references | Dz.U. L. 113/1992, Dyrektywa 92/28/EEC, W sprawie reklamy produktów leczniczych. | |
| dc.references | Dz.U. L. 136/ 2004, Dyrektywa 2004/27/EC, Zmieniająca dyrektywę 2001/83/EC w sprawie
wspólnotowego kodeksu odnoszącego się do produktów leczniczych stosowanych
u ludzi. | |
| dc.references | Dz.U. L. 311/2001, Dyrektywa 2001/83/EC, W sprawie wspólnotowego kodeksu odnoszącego
się do produktów leczniczych stosowanych u ludzi. | |
| dc.references | EFPIA, About EFPIA, http://www.efpia.org/Content/default.asp?PageID=319. | |
| dc.references | European Federation of Pharmaceutical Industries and Associations, The Pharmaceutical
Industry in Figures, EFPIA 2010. | |
| dc.references | Eurostat, Public Health Statistics. Main Tables, http://epp.eurostat.ec.europa.eu/portal/page/
portal/health/public_health/data_public_health/main_tables. | |
| dc.references | Farmindustria, Code of professional conduct Farmindustria 2009, http://www.farmindustria.
it/pubblico/02cofain.pdf. | |
| dc.references | IMS Health, Total Unaudited and Audited Global Pharmaceutical Market by Region,
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Li
ne_Data/Global%20Pharmaceutical%20Market%20By%20Region_April_2009.pdf. | |
| dc.references | Istituto di Autodisciplina pubblicitare, Codice di Autodisciplina della Comunicazione Commerciale,
http://www.iap.it/it/codice.htm. | |
| dc.references | LEEM, The French Pharmaceutical Companies Association, http://www.leem.org/medica
ment/version-anglaise-751.htm. | |
| dc.references | Lizut M., Jak ustawić lekarza, „Gazeta Wyborcza” 2006, nr 120. | |
| dc.references | Makowska M., Etyczne wyzwania współpracy pomiędzy lekarzami a przemysłem farmaceutycznym,
„Annales. Etyka w życiu gospodarczym” 2011, tom 14, nr 2. | |
| dc.references | OECD, Pharmaceutical Pricing Polices in a Global Market, OECD, Paris 2008. | |
| dc.references | Orellana C., German Doctors Links with Drug Firm Investigated, „The Lancet” 2002, nr 359. | |
| dc.references | Villanueva P., S. Peiro, J. Librero, I. Pereiro, Accuracy of Pharmaceutical Advertisements in
Medical Journals, „The Lancet” 2003, nr 361. | |
